On Friday, Novo Nordisk A/S NVO launched topline outcomes from a part 1b/2a trial with amycretin meant for once-weekly subcutaneous administration.
The trial investigated the security, tolerability, pharmacokinetics, and proof-of-concept after once-weekly subcutaneous administrations of amycretin in 125 individuals with obese or weight problems.
The trial was a mixed single ascending, a number of ascending, and dose-response trial investigating three totally different upkeep doses with a complete remedy length of as much as 36 weeks.
Additionally Learn: In style Ozempic, Wegovy Chosen For Subsequent Spherical Of Medicare Drug Value Negotiations
The first endpoint was the remedy of emergent antagonistic occasions. When evaluating the consequences of remedy if all individuals adhered to remedy from a imply baseline physique weight of 92.7 kg, individuals handled with amycretin achieved an estimated physique weight lack of 9.7% on 1.25mg (20 weeks), 16.2% on 5mg (28 weeks) and 22.0% on 20mg (36 weeks).
Individuals handled with a placebo skilled an estimated 1.9%, 2.3%, and a pair of.0% physique weight acquire, respectively.
The protection profile of amycretin was in line with incretin-based therapies.
The most typical antagonistic occasions with amycretin have been gastrointestinal, and the overwhelming majority have been gentle to average in severity.
Based mostly on the outcomes, Novo Nordisk is planning additional scientific improvement of amycretin in adults with obese or weight problems. Final week, Novo Nordisk launched headline outcomes from the STEP UP Section 3b trial within the world STEP program.
When evaluating the consequences of remedy if all individuals adhered to remedy from a imply baseline physique weight of 113 kg, individuals handled with semaglutide 7.2 mg achieved a superior weight lack of 20.7% after 72 weeks in comparison with a discount of 17.5% with semaglutide 2.4 mg and a pair of.4% with placebo.
Value Motion: NVO inventory is up 10.80% at $89.90 throughout the premarket session finally test Friday.
Learn Subsequent:
Picture by way of Shutterstock
Market Information and Knowledge dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
